AMZN
Amazon.com, Inc.
AMZN has a slight edge over EYE overall, supported by lower modeled downside and stronger modeled upside.
EYE
National Vision Holdings, Inc.
EYE offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
EYE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Healthy |
EYE's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over EYE in the historical PE scenario, which offers more potential upside but is not a forecast.
EYE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $18.57 | — |
| Current | 23x | $18.57 | — |
| Cheap | 28x | $22.52 | +21% |
| Fair | 50x | $40.68 | +119% |
| Expensive | 103x | $83.20 | +348% |
Historical ranges are pointers, not guarantees.
EYE's PE is in its cheap range at 23x. If earnings grow as analysts expect, today's price would be 16x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
EYE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect EYE's earnings to grow and its profitability to improve, with its revenue holding steady.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN's earnings per share have climbed steadily: $12.37 over the past year, up 75% from the year before, and higher year over year for 14 quarters in a row. Its recent earnings include one-off gains.
EYE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.16 | +44% |
| Q3 2026 | $0.81 | +$0.84 |
| Q2 2026 | $0.61 | +$0.79 |
| Q1 2026 | $0.57 | +$0.90 |
| Q4 2025 | $0.37 | +$0.73 |
| Q3 2025 | -$0.03 | +$0.16 |
| Q2 2025 | -$0.18 | +$0.84 |
| Q1 2025 | -$0.33 | +$0.58 |
| Q4 2024 | -$0.36 | +$0.48 |
EYE has returned to profit: it earned $0.81 per share over the past year, after losing money the year before.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over EYE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over EYE on profitability, with a higher operating margin.
EYE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $510.5M | +4.8% |
| Q2 2026 | $498.8M | +2.5% |
| Q1 2026 | $543.9M | +6.6% |
| Q4 2025 | $503.4M | +15% |
| Q3 2025 | $487.3M | +7.9% |
| Q2 2025 | $486.4M | +7.7% |
| Q1 2025 | $510.3M | -5.9% |
| Q4 2024 | $437.3M | -14% |
EYE's revenue has grown year over year for six quarters in a row: $511M last quarter, up 4.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.1% | +4.1 points |
| Q2 2026 | 4.3% | +0.9 points |
| Q1 2026 | 8.3% | +3.2 points |
| Q4 2025 | 1.3% | +7.2 points |
| Q3 2025 | 2% | +3.9 points |
| Q2 2025 | 3.4% | +3.3 points |
| Q1 2025 | 5.1% | +0.6 points |
| Q4 2024 | -5.8% | -3.2 points |
EYE's operating margin was 6.1% last quarter, up 4.1 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
EYE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $49.3M | +63% |
| Q2 2026 | -$14.1M | -133% |
| Q1 2026 | $44.1M | +267% |
| Q4 2025 | -$11.2M | -$9.5M |
| Q3 2025 | $30.3M | +647% |
| Q2 2025 | $42.4M | +33% |
| Q1 2025 | $12M | +202% |
| Q4 2024 | -$1.7M | +$11.3M |
EYE has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
EYE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -533K shares |
| 1 year | -1.4% | -1.1M shares |
| 3 years | +2.4% | +1.9M shares |
| 5 years | -17% | -16.4M shares |
| Available history | -2.1% | -1.7M shares |
EYE has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $21.4M |
| Q2 2026 | $20.1M |
| Q1 2026 | $10.5M |
| Q4 2025 | $650,000 |
| Q3 2025 | $876,000 |
| Q2 2025 | $55,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $273,000 |
EYE spent $53M buying back its own shares over the past year, more than ten times what it spent the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over EYE on leverage, with a lower net debt burden relative to earnings.
EYE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.2x | Elevated |
EYE's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
EYE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 33.1 | Neutral |
EYE's weekly RSI is 49 (neutral) and its Stochastic is 33 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN has the edge over EYE on valuation relative to its sector.
EYE PE vs Consumer Cyclical Sector
| Metric | EYE | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 18x | 27% above |
| PE % | 7 | 47 | 40 pts below |
EYE is trading at 23x earnings, a 27% premium to the Consumer Cyclical sector's median of 18x.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over EYE on trend strength, trading above more of its moving averages.
EYE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.4 | 7% above |
| 20 week MA | $18.4 | 0.7% above |
| 50 week MA | $22.0 | 16% below |
| 100 week MA | $20.5 | 9.5% below |
| 200 week MA | $19.7 | 5.6% below |
EYE has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 5.6% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over EYE on returns for 2026, with the stronger performance.
EYE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $47.3 | +43% |
| 2021 | $47.3 | $47.8 | +1.1% |
| 2022 | $47.8 | $38.7 | -19% |
| 2023 | $38.7 | $20.9 | -46% |
| 2024 | $20.9 | $10.6 | -49% |
| 2025 | $10.6 | $28.0 | +165% |
| 2026 YTD | $28.0 | $18.6 | -34% |
EYE's yearly returns have swung widely, from +165% in 2025 to −49% in 2024. It's down 34% so far in 2026.